Baloney from the FDA on LYMErix Arthritis Cases (Marty Schreifer happens to be one of the CDC-IDSA crooks).

[Mort Zuckerman]

To: emcsw...@niaid.nih.gov, afa...@niaid.nih.gov,
Spin...@yahoogroups.com, kshe...@calea.org, fit...@gmail.com,
patrick.f...@usdoj.gov, model...@sbcglobal.net,
jdr...@nejm.org, let...@courant.com, Jgerb...@cdc.gov,
michae...@po.state.ct.us, con...@po.state.ct.us, executive-
edi...@nytimes.com, managin...@nytimes.com, news-
ti...@nytimes.com, the-...@nytimes.com, biz...@nytimes.com,
for...@nytimes.com, nati...@nytimes.com, dv...@cdc.gov,
brigidc...@optonline.net, tr...@hotmail.com, illino...@aol.com,
jle...@courant.com, tinaj...@yahoo.com, jhorn...@fff.org,
thomas...@usdoj.gov, thoma...@po.state.ct.us,
kur...@washpost.com, georg...@washpost.com, p...@allegorypress.com,
commissi...@po.state.ct.us, brans...@comcast.net,
vts...@comcast.net, o...@po.state.ct.us, freet...@charter.net,
scott....@po.state.ct.us, govern...@po.state.ct.us,
attorney...@po.state.ct.us, randall...@usdoj.gov,
Robert....@yale.edu, edi...@greenwich-post.com,
harol...@yale.edu
Cc: fra...@ucia.gov, dr-ahma...@president.ir,
eugener...@washpost.com, afa...@niaid.nih.gov,
bmi...@newstimes.com, tr...@hotmail.com, rast...@aol.com,
billc...@gmail.com, amcg...@rms-law.com, rjmu...@aol.com,
paulcrai...@yahoo.com, sidney_b...@yahoo.com,
criminal...@usdoj.gov, karla.d...@usdoj.gov,
christophe...@usdoj.gov, richar...@yale.edu,
harol...@yale.edu, james.p...@yale.edu, inq...@aldf.com,
ly...@idsociety.org

Subject: Baloney from the FDA on LYMErix Arthritis Cases (Marty
Schreifer happens to be one of the CDC-IDSA crooks).

Date: Apr 2, 2009 11:50 AM

Baloney.

(article below)


No one was ever sure free OspA molecules
were ever the actual vaccine because of
the clumping or aggregation seen in the
smudged blots, and confirmed by the Mass-Spec
study done by the Korean Chemists:
http://www.actionlyme.org/PAM3CYS_LYME_HIV.ht

Even Alan Barbour claims OspA sticks to itself.

Look again you friggin TARDS:
http://www.actionlyme.org/DICKSON_FDA_SUBMISSION_FULL.htm


These clowns need to explain the smudged blots before
claiming LYMErix didn't do anything. And run an HPLC
study on the vaccine vials - AS IS - no post-columns
or double separation sample prep.


And most of all, we're not interested in the
arthritis outcomes of OspA vaccination, since
there were about 3 such people. The rest
were the immune suppressed or chronic Lyme
like outcomes:
http://www.actionlyme.org/PAM3CYS_IMMUNE_SUPPRESSION.htm
as I told the FDA:
http://www.fda.gov/OHRMS/DOCKETS/ac/01/slides/3680s2_11.pdf


If there are more than ~3 arthritis patients
from vaccination, then look for mycoplasmal
DNA in the synovial fluid of these victims
(assuming they had the oligoarthritis claimed
by Steere to be characteristic of Lyme, although
no one yet has been able to explain it
except SmithKline who hypothesized that this
was due to persisting spirochetes in joints:
http://www.fda.gov/OHRMS/DOCKETS/ac/01/slides/3680s2.htm
See Yves Lobet's presentation) due to the
immune suppression/tolerization in response
to such a large BOLUS of this fungal antigen:
http://www.actionlyme.org/PAM3CYS_IMMUNE_SUPPRESSION.htm

The same thing happened with the HIV and the
tuberculosis "vaccines."

TOLERANCE to the fungal antigens, and the normal
immune response being turned off/gummed up.


I really can't believe this crap from the FDA.
They're supposed to know how to do stuff, and
most of all *WHY.*

I really can't believe they get paid - by us -
for being that brainless.


Ya know what it is, it's this character
Marty Schreifer, who happens to be one of
the CDC-IDSA crooks. Therefore, this is yet
another "bogus article"
http://www.actionlyme.org/TICK_BITE_CONSPIRACY.htm



Kathleen M. Dickson
http://www.actionlyme.org

http://www.ncbi.nlm.nih.gov/pubmed/19333928?ordinalpos=1&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_DefaultReportPanel.Pubmed_RVDocSum

: Arthritis Rheum. 2009 Mar 30;60(4):1179-1186. [Epub ahead of print]
Click here to read Links
HLA type and immune response to Borrelia burgdorferi outer surface
protein a in people in whom arthritis developed after Lyme disease
vaccination.
Ball R, Shadomy SV, Meyer A, Huber BT, Leffell MS, Zachary A,
Belotto M, Hilton E, Bryant-Genevier M, Schriefer ME, Miller FW, Braun
MM.

Center for Biologics Evaluation and Research, FDA, Rockville,
Maryland.

OBJECTIVE: To investigate whether persons with treatment-resistant
Lyme arthritis-associated HLA alleles might develop arthritis as a
result of an autoimmune reaction triggered by Borrelia burgdorferi
outer surface protein A (OspA), the Lyme disease vaccine antigen.
METHODS: Persons in whom inflammatory arthritis had developed after
Lyme disease vaccine (cases) were compared with 3 control groups: 1)
inflammatory arthritis but not Lyme disease vaccine (arthritis
controls), 2) Lyme disease vaccine but not inflammatory arthritis
(vaccine controls), and 3) neither Lyme disease vaccine nor
inflammatory arthritis (normal controls). HLA-DRB1 allele typing,
Western blotting for Lyme antigen, and T cell reactivity testing were
performed. RESULTS: Twenty-seven cases were matched with 162 controls
(54 in each control group). Odds ratios (ORs) for the presence of 1 or
2 treatment-resistant Lyme arthritis alleles were 0.8 (95% confidence
interval [95% CI] 0.3-2.1), 1.6 (95% CI 0.5-4.4), and 1.75 (95% CI
0.6-5.3) in cases versus arthritis controls, vaccine controls, and
normal controls, respectively. There were no significant differences
in the frequency of DRB1 alleles. T cell response to OspA was similar
between cases and vaccine controls, as measured using the stimulation
index (OR 1.6 [95% CI 0.5-5.1]) or change in uptake of tritiated
thymidine (counts per minute) (OR 0.7 [95% CI 0.2-2.3]), but cases
were less likely to have IgG antibodies to OspA (OR 0.3 [95% CI
0.1-0.8]). Cases were sampled closer to the time of vaccination
(median 3.59 years versus 5.48 years), and fewer cases had received 3
doses of vaccine (37% versus 93%). CONCLUSION: Treatment-resistant
Lyme arthritis alleles were not found more commonly in persons who
developed arthritis after Lyme disease vaccination, and immune
responses to OspA were not significantly more common in arthritis
cases. These results suggest that Lyme disease vaccine is not a major
factor in the development of arthritis in these cases.

"[Real] scientists are *fiercely* independent. That's the good
news."-- NIH's Top Fool, Anthony Fauci